Gts Securities LLC Aurinia Pharmaceuticals Inc. Put Options Transaction History

Gts Securities LLC

  • $45.4 Billion
  • Q3 2024

Put Options

5 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 13, 2024
BUY
$5.32 - $7.33 $57,456 - $79,164
10,800 Added 11.29%
106,500 $780,000
Q2 2024

Aug 14, 2024
SELL
$4.81 - $5.78 $728,714 - $875,670
-151,500 Reduced 61.29%
95,700 $546,000
Q1 2024

May 15, 2024
BUY
$4.93 - $9.31 $1.08 Million - $2.05 Million
220,000 Added 808.82%
247,200 $1.24 Million
Q4 2023

Feb 14, 2024
BUY
$7.13 - $9.49 $66,309 - $88,257
9,300 Added 51.96%
27,200 $244,000
Q3 2023

Nov 15, 2023
BUY
$7.77 - $12.27 $139,083 - $219,633
17,900 New
17,900 $139,000

Others Institutions Holding AUPH

# of Institutions
209
Shares Held
58.7M
Call Options Held
1.14M
Put Options Held
1.51M
View Full List

About Aurinia Pharmaceuticals Inc.

AUPH Quotes by TradingView
  • Ticker AUPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,892,000
  • Market Cap $1.15B
  • Description
  • Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...
More about AUPH
Track This Portfolio

Track Gts Securities LLC Portfolio

Follow Gts Securities LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gts Securities LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email